Biogen Pharmachem Industries share price
BIOGEN PHARMACHEM INDUSTRIES LIMITED · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1996
Last close ₹0.24₹0.00 (0.00%)
Share price at the BSE close on 27 Oct 2026. Previous close ₹0.24.
27 Oct: open ₹0.24, high ₹0.25, low ₹0.24
52-week range of traded prices to 27 Oct 2026
₹0.23Low, 23 Oct 2026₹0.73High, 27 Oct 2025
- Next results date: the board meets on 3 Nov 2026 to consider: quarterly results. Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹25 Cr3,446th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.26
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −0.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 26,53,287
Results
Standalone; ₹ crore.Biogen Pharmachem Industries quarterly results
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹0.44 Crdown 23.31%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing. Net profit in the glossary
- ₹0.22 CrQuarter to Mar 2026: −₹0.36 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 49.9%
Revenue by quarter
Peak revenue ₹1.54 Cr, quarter to Jun 2025; lowest ₹0.00 Cr, quarter to Sep 2024
Net profit by quarter, a loss in red
- Net profit
- Loss
Back to profit in the quarter to Jun 2026, ₹0.22 CrA loss in 4 of the 7 quarters with results on record
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | – | 1.54 | 0.00 | 0.00 | 0.58 | 0.44 |
| Net profit | −1.00 | −0.31 | – | 1.34 | −0.49 | 0.46 | −0.36 | 0.22 |
| Net margin | – | – | – | 87.2% | – | – | −62.1% | 49.9% |
Standalone. The last eight quarters. The latest is shaded. No results on record for the quarter to Mar 2025.
Year to Mar 2026
- Revenue
- ₹2.56 Cr
- Net profit
- ₹0.86 Cr
- Net margin
- 33.6%
Revenue by year
- Revenue
- Loss
Peak revenue ₹2.56 Cr, year to Mar 2026; lowest −₹6.58 Cr, year to Mar 2018
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 5 of the 9 years with results on record
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | – | −6.58 | 0.95 | 0.00 | 1.62 | 2.16 | 0.83 | – | – | 2.56 |
| Net profit | −0.12 | −6.67 | 0.02 | −0.12 | −1.60 | −0.01 | 0.46 | 1.93 | – | 0.86 |
| Net margin | – | 101.4% | 1.7% | – | −98.8% | −0.4% | 55.0% | – | – | 33.6% |
Standalone. Years to March. The latest is shaded. No results on record for the year to Mar 2025.
Valuation
Today, against the company's own history. Not shown, P/E: a results filing in the last twelve months restated the quarters before it inside its year to date, so the four quarters as the company reported them do not add to a twelve-month profit; the ratio returns once the trailing year no longer holds a quarter from before the restatement. Dividend yield is not shown: no dividend in the years on record.Biogen Pharmachem Industries PE ratio and valuation
Price to book
At or below today's level on 0.4% of 1,125 trading days over the last 5 years.
LowestHighest
Its median1.05Industry median1.48
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −46.9% | – | – | 0.0% |
| 3 years | −4.7% | +10.9% | −14.1% | 0.0% |
| 5 years | +19.4% | – | – | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 3 and 5 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Biogen Pharmachem Industries competitors and peers
Other Financial Services, 112 listed companies, priced on 27 Oct 2026. The table lists the 8 companies closest to Biogen Pharmachem Industries in market cap.Finance companies
Biogen Pharmachem Industries is not on the chart: it has no P/E or return on equity today
| Company | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
 CMX HoldingsCMXLTD | 28 | – | – | – | – | – | −30.3% | – | – | 0.00% |
 ISL ConsultingISLCONSUL | 26 | – | 2.41 | −18.6% | – | −2.7% | −3.5% | – | – | 0.00% |
 Vertex SecuritiesVERTEX | 25 | – | 2.19 | −13.6% | – | −25.8% | – | – | – | 0.00% |
 Bridge SecuritiesBRIDGESE | 25 | 34.96 | 3.80 | −17.0% | −32.7% | 13.3% | 12.2% | – | – | 0.00% |
 Longspur International VenturesLONGSPUR | 24 | 48.52 | – | −55.7% | −23.7% | 1.7% | 1.8% | – | – | 0.00% |
 Jindal CapitalJINDCAP | 23 | 18.60 | 1.90 | +27.2% | – | 10.7% | – | 4.77% | 12.43% | 0.00% |
 West Leisure ResortsWESTLEIRES | 22 | – | – | −33.4% | – | – | – | – | – | 0.00% |
 KJMC Corporate Advisors (India)KJMCCORP | 21 | 10.35 | 0.37 | +36.1% | +93.1% | 3.2% | 5.7% | – | – | 1.31% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record; for ROCE and EV/EBITDA, where the company is a lender or an insurer; for NIM and ROA, where the company does not file a lender's accounts. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page. ROA is the year's profit over average total assets. NIM is net interest income over average loans and investments.
Latest announcements
Routine notices left out.Biogen Pharmachem Industries announcements
Oct 2026
23 Oct · Board meeting
Meeting on 3 Nov 2026: quarterly results
Sep 2026
29 Sep · Meeting
29 Sep · Meeting
Biogen Pharmachem Industries annual report, year to Mar 2026
Biogen Pharmachem Industries share price by year
Each calendar year to 2025.Biogen Pharmachem Industries share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 0.59 | −41.5% | 1.02 | 0.59 |
| 2024 | 1.01 | −15.1% | 1.51 | 0.88 |
| 2023 | 1.19 | +69.5% | 1.52 | 0.47 |
| 2022 | 0.70 | +34.4% | 1.56 | 0.55 |
| 2021 | 0.52 | +165.2% | 1.09 | 0.16 |
| 2020 | 0.20 | +4.5% | 0.31 | 0.16 |
| 2019 | 0.19 | −8.3% | 0.28 | 0.16 |
| 2018 | 0.21 | +26.3% | 0.24 | 0.16 |
| 2017 | 0.16 | −42.4% | 0.29 | 0.16 |
| 2016 | 0.28 | +57.1% | 0.30 | 0.16 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2020 is from its first session, 20 Jan 2020. 2018 is from its first session, 5 Apr 2018. The 2017 close is its last trade, on 1 Aug 2017.
Recent sessions
The 9 trading days to 26 Oct 2026, as traded on BSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 26 Oct 2026 | 0.25 | 0.25 | 0.23 | 0.24 | 0.24 | 23,87,995 |
| 23 Oct 2026 | 0.25 | 0.25 | 0.23 | 0.24 | 0.24 | 24,98,763 |
| 22 Oct 2026 | 0.24 | 0.25 | 0.24 | 0.24 | 0.24 | 25,33,493 |
| 21 Oct 2026 | 0.25 | 0.26 | 0.24 | 0.24 | 0.25 | 49,77,943 |
| 19 Oct 2026 | 0.26 | 0.26 | 0.24 | 0.25 | 0.25 | 31,26,057 |
| 16 Oct 2026 | 0.25 | 0.26 | 0.24 | 0.26 | 0.25 | 61,69,986 |
| 15 Oct 2026 | 0.26 | 0.26 | 0.24 | 0.26 | 0.25 | 68,87,904 |
| 14 Oct 2026 | 0.28 | 0.31 | 0.25 | 0.25 | 0.27 | 3,32,24,164 |
| 13 Oct 2026 | 0.26 | 0.29 | 0.26 | 0.27 | 0.28 | 76,15,558 |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus share history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 15 May 2026 | Bonus | 0.8571 | Holders received 1 bonus share for every 6 held. |
| 10 Jul 2013 | Price move | – | Between two trading sessions the price moved by a fifth or more. No corporate action is on record. Not adjusted for. |
| 9 Jul 2013 | Price move | – | Between two trading sessions the price moved by a fifth or more. No corporate action is on record. Not adjusted for. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout. Any other event is noted and not adjusted for.
Company details
- BSE code
- 531752
- ISIN
- INE703D01023
- Industry
- Finance
- Website
- www.biogenpharma.bar
- CIN
- L51100GJ1995PLC026702
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1995
- Registered office
- Shop No. 8, First Floor, Makers - 1 Building, Jawahar Road, Rajkot 360001, Gujarat
- Share registrar
- Satellite Corporate Services Pvt Ltd
- Keeps the register of shareholders and handles transfers and dividend payments